ATRA

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.

Wall Street analysts forecast ATRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRA is 17.50 USD with a low forecast of 17.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Atara Biotherapeutics Inc revenue for the last quarter amounts to 3.45M USD, decreased -91.41 % YoY.

Atara Biotherapeutics Inc. EPS for the last quarter amounts to -0.32 USD, decreased -89.08 % YoY.

Atara Biotherapeutics Inc (ATRA) has 153 emplpoyees as of December 15 2025.

Today ATRA has the market capitalization of 129.75M USD.